Chapter 002. Global Issues in Medicine (Part 5) ppsx

Chapter 002. Global Issues in Medicine (Part 5) AIDS Chapter 182 provides an overview of the AIDS epidemic in the world today. Here we will limit ourselves to a discussion of AIDS in the developing world. Lessons learned in tackling AIDS in resource-constrained settings are highly relevant to discussions of other chronic diseases, including noncommunicable diseases, for which effective therapies have been developed. We highlight several of these lessons below. In the United States, the availability of highly active antiretroviral therapy (ART) for AIDS has transformed this disease from an inescapably fatal destruction of cell-mediated immunity into a manageable chronic illness. In developing countries, treatment has been offered more broadly only since 2003, and only in the summer of 2006 did the number of patients receiving treatment exceed 25% of the number who currently need it. (It remains to be seen how many of these fortunate few are receiving ART regularly and with the requisite social support.) Before 2003, many arguments were raised to justify not moving forward rapidly with ART programs for people living with HIV/AIDS in resource-limited settings. The standard litany included the price of therapy compared to the poverty of the patient, the complexity of the intervention, the lack of infrastructure for laboratory monitoring, and the lack of trained health care providers. Narrow cost-effectiveness arguments that created false dichotomies— prevention or treatment, rather than both—too often went unchallenged. The greatest obstacle at the time was the ambivalence, if not outright silence, of political leaders and experts in public health. The cumulative effect of these factors was to condemn to death tens of millions of poor people in developing countries who had become ill as a result of HIV infection. The inequity between rich and poor countries in access to HIV treatment has rightly given rise to widespread moral indignation. In several middle-income countries, including Brazil, visionary programs have bridged the access gap. Other innovative projects pioneered by international nongovernmental organizations (NGOs) in diverse settings have clearly established that a very simple approach to ART, based on intensive community engagement and support, can achieve remarkable results. In 2000, the United Nations Accelerating Access Initiative finally brought the research-based and generic pharmaceutical industries into play, and AIDS drug prices have since fallen significantly. At the same time, easier-to-administer fixed- dose combination drugs have become more widely available. Building on these lessons, the WHO advocated a public health approach to the treatment of people with AIDS in resource-limited settings. This approach, which was derived from models of care pioneered by the NGO Partners In Health and other groups, proposed standard first-line treatment regimens based on a simple five-drug formulary, with a more complex (and, up to now, more expensive) set of second-line options in reserve. Common clinical protocols were standardized, and intensive training packages for health and community workers were developed and implemented in many countries. These efforts were supported by unprecedented funding through the World Bank, the Global Fund, and PEPFAR. In 2003, the lack of access to ART was declared a global public-health emergency by the WHO and UNAIDS, and the two agencies launched the "3 by 5 initiative," setting an ambitious target: having 3 million people in developing countries on treatment by the end of 2005. Many countries have since set corresponding national targets and have worked to integrate ART into their national AIDS programs and health systems and to harness the synergies between HIV/AIDS treatment and prevention activities. The G8 (Gleneagles) 2005 communiqué endorsing universal access to HIV treatment by 2010 was another major step forward. It is clear by now that the claims made for the efficacy of ART are well founded: in the United States, such therapy has prolonged life by an estimated 13 years per patient on average—a success rate that would compare favorably with that of almost any treatment for cancer or for complications of coronary artery disease. Further lessons with implications for policy and action have come from efforts that are now under way in the developing world. During the past decade, through experiences in >50 countries thus far, the world has seen that ambitious policy goals, adequate funding, and knowledge about implementation can dramatically transform the prospects of people living with HIV infection in developing nations. . Chapter 002. Global Issues in Medicine (Part 5) AIDS Chapter 182 provides an overview of the AIDS epidemic in the world today. Here we will limit ourselves to a discussion of AIDS in. of AIDS in the developing world. Lessons learned in tackling AIDS in resource-constrained settings are highly relevant to discussions of other chronic diseases, including noncommunicable. infection. The inequity between rich and poor countries in access to HIV treatment has rightly given rise to widespread moral indignation. In several middle-income countries, including Brazil,